Covid-19 Therapeutic Drugs Concocted By BUMN Pharmaceuticals Ready For Sale Next Week

Illustration. (Photo: Unsplash)

JAKARTA - The President Director of the BUMN Pharmacy Holding, Bio Farma, Honesti Basyir, said that the drug for handling COVID-19, prepared by the BUMN Pharmacy Holding, is ready for use. This drug will be marketed by PT Kimia Farma Tbk and PT Indofarma Tbk.

Honesti said two members of BUMN Holding Pharmaceuticals, namely PT Kimia Farma Tbk, are now able to produce drugs for handling COVID-19, namely Favipiravir which can be used for COVID-19 therapy. Meanwhile, PT Indofarma, Tbk is ready to market the anti-corona drug Remdesivir under the trade name Desrem.

Furthermore, he explained, this drug was produced by Mylan Laboratories Limited, under license from Gilead Sciences Inc, Foster City and the United States of America.

"The joining of pharmaceutical BUMN entities in a holding umbrella is expected to assist the government in accelerating the response to the COVID-19 pandemic in Indonesia. Both in terms of prevention through vaccines, treatment through drugs and provision of multivitamins, as well as the provision of medical devices," he said in Jakarta, Monday. , October 5.

Apart from Favipivar, PT Kimia Farma Tbk, and its subsidiary, PT Phapros, Tbk, have also succeeded in producing several drugs for the treatment of COVID-19, including Chloroquine, Hydroxychloroquine, Azithromycin, Favipiravir, Dexamethasone and Methylprednisolone.

Not only that, Kimia Farma also produces several multivitamins that increase endurance, such as Vitamin C (tablets and injection), Becefort, Fituno and Geriavita as additional products to maintain endurance.

Kimia Farma President Director Verdi Budidarmo said that the type of Favipiravir drug that can be used for COVID-19 therapy can be produced by Kimia Farma itself, and is the first product in Indonesia to be developed by State-Owned Enterprises (BUMN), and has received a Permit Number. Edar (NIE) from the Food and Drug Supervisory Agency (BPOM).

"And it will be distributed to all health services in accordance with government regulations," he explained.

- https://voi.id/berita/15623/trump-diobati-dengan-campur-antibodi-eksperimental-covid-19

- https://voi.id/berita/15427/kalbe-farma-siap-d Distribut-remdesivir-untuk-pasien-covid-19-di-indonesia

- https://voi.id/berita/15434/obat-covid-19-kalbe-farma-dijual-rp3-juta-per-dosis

Meanwhile, another member of the BUMN Pharmacy Holding, PT Indofarma Tbk, along with all its business groups (companies) support the government's efforts to suppress the spread of COVID-19 in the country through various types of products, including Oseltamivir 75gr Caps which is a leading antiviral which currently has become a reference as a COVID-19 treatment protocol in various hospitals.

President Director of Indofarma Arief Pramuhanto said, Oseltamivir 75 gr Caps is a product that has a Domestic Content Level certificate of 40.06 percent, has been produced by PT Indofarma, Tbk, with a production capacity of 4.9 million capsules per month, so it is expected to be able to sufficient for the needs of the Indonesian people.

Another product for handling COVID-19 is Desrem Remdesivir Inj 100 mg, which is an antiviral product produced by Mylan Laboratories Ltd, which will be marketed by PT Indofarma Tbk, in the near future.

"The product that we will market in the near future is Desrem Remdesivir Inj 100mg, which has received Emergency Use Authorization (EUA) approval in Indonesia and has been approved by BPOM through the issuance of a marketing license number which has been issued on September 30, 2020. It will start marketing this week. ahead, "he said.

Remdesivir is a drug used for inpatients with COVID-19 in moderate to severe conditions. Then for the availability of stocks for this month, there are already around 400,000 vials at prices that are certainly affordable for the public.